BRAIN/CNS TUMORS
P2/3 Randomized Study of Toca 511 & Toca FC Versus SOC in Subjects Undergoing Surgery for Recurrent GBM/AA
Phase: Phase III, Phase II
Type: Treatment
Age: 18 to 75
Trial IDs: Tg 511-15-01, NCI-2015-01577, NCT02414165
Ponatinib Hydrochloride in Treating Patients with Bevacizumab-Refractory Glioblastoma
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 15-163, NCI-2015-01746, NCT02478164
Correlation between Genetic and Imaging Information in Patients with Newly Diagnosed Glioblastoma before Surgery
Phase: No phase specified
Type: Biomarker/Laboratory analysis, Diagnostic
Age: Not specified
Trial IDs: OSU-15019, NCI-2015-00873, NCT02590497
DNX-2401 With Interferon Gamma for Recurrent Glioblastoma or Gliosarcoma Brain Tumors
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 2401BT-IFN-001, NCI-2014-01929, NCT02197169
Neoantigen-based Glioblastoma Vaccine and Poly-ICLC Vaccine in Treating Patients with Newly Diagnosed Glioblastoma
Phase: No phase specified
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 201510022, NCI-2015-01776, NCT02510950
BREAST CANCER
SANDPIPER Study: A Study Of Taselisib + Fulvestrant Versus Placebo + Fulvestrant In Patients With Advanced or Metastatic Breast Cancer Who Have Disease Recurrence or Progression During or After Aromatase Inhibitor Therapy
Phase: Phase III
Type: Treatment
Age: 18 and over, postmenopausal
Trial IDs: GO29058, NCI-2015-01649, 2014-003185-25, NCT02340221
Boost Radiation Therapy before Surgery in Treating Patients with Breast Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: Not specified
Trial IDs: Pro00063936, NCI-2015-01625, NCT02482389
Prophylactic Topical Agents in Reducing Radiation-Induced Dermatitis in Patients with Non-inflammatory Breast Cancer or Breast Cancer In Situ
Phase: Phase II
Type: Biomarker/Laboratory analysis, Supportive care
Age: 21 and over
Trial IDs: URCC14079, NCI-2015-00869, NCT02556632
Palbociclib and Bazedoxifene in Treating Patients with Hormone Receptor Positive Locally Advanced or Metastatic Breast Cancer That Cannot Be Removed by Surgery
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 15-060, NCI-2015-01604, NCT02448771
A Study of Ipatasertib (GDC-0068) in Combination With Paclitaxel as Neoadjuvant Treatment for Patients With Early Stage Triple Negative Breast Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: GO29505, NCI-2015-01653, 2014-003029-16, NCT02301988
Pegylated Liposomal Doxorubicin Hydrochloride and Carboplatin Followed by Surgery and Paclitaxel in Treating Patients with Triple Negative Stage II-III Breast Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 041401, NCI-2014-02029, NCT02315196
CERVICAL CANCER
Image Guided Hypofractionated Radiation Therapy in Treating Patients with Stage IB-IVB Cervical Cancer
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: STU 082013-064, NCI-2015-01672, NCT02045433
COLORECTAL CANCER
Isoquercetin in Preventing Venous Thromboembolic Events in Patients with Pancreatic Cancer, Non-small Cell Lung Cancer, or Colorectal Cancer That is Advanced or Cannot Be Removed by Surgery
Phase: Phase III, Phase II
Type: Supportive care
Age: 18 and over
Trial IDs: 14-114, NCI-2015-01705, NCT02195232
Intensity Modulated Radiation Therapy and Quality of Life in Patients With Rectal Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 09-157, NCI-2010-01327, NCT01148056
Combination Chemotherapy and Bevacizumab with or without PRI-724 in Treating Patients with Newly Diagnosed Metastatic Colorectal Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 3C-13-3, NCI-2015-00436, NCT02413853
Study of Pembrolizumab (MK-3475) as Monotherapy in Participants With Previously-Treated Locally Advanced Unresectable or Metastatic Colorectal Cancer (MK-3475-164/KEYNOTE-164)
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 3475-164, NCI-2015-01721, 2015-001852-32, NCT02460198
Health Education Materials With or Without a Physical Activity Program for Patients Who Have Undergone Treatment for High-Risk Stage II or Stage III Colon Cancer
Phase: Phase III
Type: Biomarker/Laboratory analysis, Educational/Counseling/Training
Age: 18 and over
Trial IDs: CO21, NCI-2015-01662, CAN-NCIC-CO21, CDR0000629834, NCT00819208
Study of LGX818 and Cetuximab or LGX818, BYL719, and Cetuximab in BRAF Mutant Metastatic Colorectal Cancer
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CLGX818X2103, NCI-2013-02457, 2012-002138-35, NCT01719380
ESOPHAGEAL CANCER
Regorafenib in Treating Patients with Locally Advanced Cancer of the Esophagus or Gastroesophageal Junction Who Have Completed Chemoradiation Therapy and Surgery
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: RU021212I, NCI-2015-01699, NCI-2014-01962, NCT02234180
HEAD & NECK/ORAL CANCER
A Phase Ib/II Study of BYL719 and Cetuximab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CBYL719X2104, NCI-2013-00766, 2011-006017-34, NCT01602315
Pembrolizumab and Vorinostat in Treating Patients with Recurrent Squamous Cell Head and Neck Cancer or Salivary Gland Cancer That Is Metastatic and/or Cannot Be Removed by Surgery
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 9383, NCI-2015-01310, MK-3475, NCT02538510
Hypofractionated Radiation Therapy Followed by Surgery in Treating Patients with Advanced Squamous Cell Carcinoma of the Oral Cavity
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 031401, NCI-2014-02215, NCT02295540
KIDNEY CANCER
High-Dose Aldesleukin and Stereotactic Body Radiation Therapy in Treating Patients with Metastatic Kidney Cancer
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: STU 012013-041, NCI-2015-01670, NCT01896271
LEUKEMIA/LYMPHOMA/MDS
Efficacy and Safety of Idelalisib in Combination With Obinutuzumab Compared to Chlorambucil in Combination With Obinutuzumab for Previously Untreated Chronic Lymphocytic Leukemia
Phase: Phase III
Type: Treatment
Age: 65 and over
Trial IDs: GS-US-312-0118, NCI-2015-01760, 2013-004551-20, NCT01980875
Treatment for Advanced B-Cell Lymphoma
Phase: Phase II
Type: Treatment
Age: 3 to 31
Trial IDs: NYMC-157, NCI-2015-01702, L 10,753, NCT01859819
Combination Chemotherapy, Rituximab, and Ixazomib Citrate in Treating Patients with Non-Hodgkin Lymphoma
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: NU 14H09, NCI-2015-00400, STU00200596, X16042, NCT02481310
Brentuximab Vedotin, Doxorubicin Hydrochloride, and Dacarbazine in Treating Patients with Previously Untreated Stage I-IIA Non-bulky Classical Hodgkin Lymphoma
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 15-196, NCI-2015-01592, 35-IST-029, NCT02505269
CIP-613, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients with Relapsed or Refractory Acute Myeloid Leukemia or Granulocytic Sarcoma
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: CCCWFU 22215, NCI-2015-01002, IRB00033779, NCT02484391
Combination Chemotherapy with or without Rituximab, Imatinib Mesylate, or Dasatinib in Treating Patients with Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 2008-0598, NCI-2011-00861, NCT01319981
AT13387 in Treating Patients with Relapsed or Refractory Anaplastic Large Cell Lymphoma, Mantle Cell Lymphoma, or Diffuse Large B-cell Lymphoma
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 9875, NCI-2015-01681, NCT02572453
LIVER CANCER
A Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/r With or Without Dasabuvir and With or Without Ribavirin in Chronic Hepatitis C Virus Genotype 1 or 4 Infected Adults With Successfully Treated Early Stage Hepatocellular Carcinoma
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: M14-726, NCI-2015-01664, 2015-001049-10, NCT02504099
Phase Ib/2, Multicenter, Dose Escalation Study of DCR-MYC in Patients With Hepatocellular Carcinoma
Phase: Phase II, Phase I
Type: Treatment
Age: Over 18
Trial IDs: DCR-MYC-102, NCI-2015-01659, NCT02314052
LUNG CANCER/MESOTHELIOMA
Isoquercetin in Preventing Venous Thromboembolic Events in Patients with Pancreatic Cancer, Non-small Cell Lung Cancer, or Colorectal Cancer That is Advanced or Cannot Be Removed by Surgery
Phase: Phase III, Phase II
Type: Supportive care
Age: 18 and over
Trial IDs: 14-114, NCI-2015-01705, NCT02195232
Ceritinib and Stereotactic Ablative Radiation Therapy in Treating Patients with ALK-Rearranged Metastatic Lung Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 042015-076, NCI-2015-01632, NCT02513667
Olaparib and Temozolomide in Treating Patients with Recurrent Small Cell Lung Cancer
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 15-121, NCI-2015-01724, NCT02446704
A Phase III Study of MPDL3280A (Anti-PD-L1 Antibody) in Combination With Carboplatin + Nab-Paclitaxel in Patients With Non-Squamous Non-Small Cell Lung Cancer [IMpower 130]
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: GO29537, NCI-2015-01602, 2014-003206-32, NCT02367781
Alectinib and Bevacizumab in Treating Patients with ALK-positive Stage IIIB-IV Non-small Cell Lung Cancer
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 15-055, NCI-2015-01704, NCT02521051
AZD1775 Plus Carboplatin-Paclitaxel in Squamous Cell Lung Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: MCC-18304, NCI-2015-01598, 15.06.0034, 18304, NCT02513563
A Comparative Study of MPDL3280A (Anti-PDL1 Antibody) With Cisplatin or Carboplatin + Pemetrexed in Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC) [IMpower 110]
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: GO29431, NCI-2015-01580, 2014-003083-21, NCT02409342
Study of Efficacy and Safety of Nivolumab in Combination With EGF816 and of Nivolumab in Combination With INC280 in Patients With Previously Treated Non-small Cell Lung Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CEGF816X2201C, NCI-2015-01626, 2014-003731-20, NCT02323126
Sublobar Resection or Stereotactic Ablative Radiotherapy in Treating Patients with Stage I Non-small Cell Lung Cancer
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: STU 022015-069, NCI-2015-01676, NCT02468024
Study to Assess Safety and Efficacy of Atezolizumab (MPDL3280A) Compared to Best Supportive Care Following Chemotherapy in Patients With Lung Cancer
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: GO29527, NCI-2015-01731, NCT02486718
Study of Safety and Efficacy of LEE011 and Ceritinib in Patients With ALK-positive Non-small Cell Lung Cancer.
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: CLEE011X2110C, NCI-2015-01657, NCT02292550
Nintedanib (BIBF 1120) in Mesothelioma
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 1199.93, NCI-2013-01643, 2012-005201-48, NCT01907100
Study of the Safety and Efficacy of Amatuximab in Combination With Pemetrexed and Cisplatin in Subjects With Unresectable Malignant Pleural Mesothelioma (MPM).
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: MORAb-009-201, NCI-2015-01754, NCT02357147
MELANOMA
A Combination Clinical Study of PLX3397 and Pembrolizumab To Treat Advanced Melanoma and Other Solid Tumors
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: PLX108-14, NCI-2015-01614, KEYNOTE-103, NCT02452424
Trametinib in Treating Patients with Advanced Melanoma with BRAF Non-V600 Mutations
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: VICC MEL 1457, NCI-2014-02185, GSK1120212, MEL1457, NCT02296112
Pembrolizumab in Treating Patients with Advanced Uveal Melanoma
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: MEL1486, NCI-2015-00020, VICCMEL1486, NCT02359851
MYELOMA
A Study of Combination of Daratumumab and Velcade (Bortezomib) Melphalan-Prednisone (DVMP) Compared to Velcade Melphalan-Prednisone (VMP) in Participants With Previously Untreated Multiple Myeloma
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: CR104761, NCI-2015-01729, 2014-002272-88, 54767414MMY3007, NCT02195479
Study of Ibrutinib in Combination With Pomalidomide (Pomalyst(TM)) and Dexamethasone in Subjects With Relapsed/Refractory Multiple Myeloma
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: PCYC-1138-CA, NCI-2015-01756, PCI-32765, NCT02548962
Standard-Dose Lenalidomide, Bortezomib, and Dexamethasone or High-Dose Lenalidomide, Bortezomib, and Dexamethasone Followed by Peripheral Blood Stem Cell Transplant in Treating Patients with Multiple Myeloma
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 to 65
Trial IDs: 10-106, NCI-2010-02211, IFM/DFCI 2009, NCT01208662
Phase 1b Study of Carfilzomib Administered Once Weekly in Combination With Lenalidomide and Dexamethasone in Subjects With Multiple Myeloma
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CFZ013, NCI-2015-01611, NCT02335983
A Study to Evaluate the Safety and Pharmacokinetics of SAR650984 in Patients With Multiple Myeloma
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: TED14154, NCI-2015-01696, U1111-1163-1073, NCT02514668
Regulatory T-cell Depletion before Stem Cell Transplant in Treating Patients with Multiple Myeloma
Phase: No phase specified
Type: Supportive care, Treatment
Age: 21 to 70
Trial IDs: 10-551-B, NCI-2015-01660, NCT01526096
OVARIAN CANCER
Veliparib With Carboplatin and Paclitaxel and as Continuation Maintenance Therapy in Subjects With Newly Diagnosed Stage III or IV, High-grade Serous, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: M13-694, NCI-2015-01623, 2014-005070-11, NCT02470585
Nivolumab with or without Ipilimumab in Treating Patients with Persistent or Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: NRG-GY003, NCI-2014-02424, 9698, NCT02498600
Phase 1/2a Two-Arm Dose-Escalation Study of BAX69 in Subjects With Malignant Ascites of Ovarian Cancer
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 391402, NCI-2015-01741, NCT02540356
Tivozanib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: NU12G11, NCI-2013-00748, STU00073756, NCT01853644
PANCREATIC CANCER
Isoquercetin in Preventing Venous Thromboembolic Events in Patients with Pancreatic Cancer, Non-small Cell Lung Cancer, or Colorectal Cancer That is Advanced or Cannot Be Removed by Surgery
Phase: Phase III, Phase II
Type: Supportive care
Age: 18 and over
Trial IDs: 14-114, NCI-2015-01705, NCT02195232
Study of Ibrutinib vs Placebo, in Combination With Nab-paclitaxel and Gemcitabine, in the First Line Treatment of Patients With Metastatic Pancreatic Adenocarcinoma (RESOLVE)
Phase: Phase III, Phase II
Type: Treatment
Age: 18 and over
Trial IDs: PCYC-1137-CA, NCI-2015-01722, NCT02436668
Immunotherapy and SBRT Study in Borderline Resectable Pancreatic Cancer
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: NLG0605, NCI-2015-01697, 1409-1350, NCT02405585
Stereotactic Body Radiation Therapy in Treating Patients with Pancreatic or Ampulla of Vater Cancer That Cannot Be Removed by Surgery
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 16866B, NCI-2015-01656, NCT01342354
S1505: Combination Chemotherapy or Gemcitabine Hydrochloride and Paclitaxel Albumin-Stabilized Nanoparticle Formulation before Surgery in Treating Patients with Pancreatic Cancer That Can Be Removed by Surgery
Phase: Phase II
Type: Treatment
Age: 18 to 75
Trial IDs: S1505, NCI-2015-01236, NCT02562716
PEDIATRIC CANCERS
UVADEX(R) and ECP for the Treatment of Pediatric Patients With Steroid Refractory Acute Graft Versus Host Disease
Phase: Phase III
Type: Treatment
Age: 1 to 21
Trial IDs: TKS-2014-001, NCI-2015-01646, NCT02524847
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Preliminary Efficacy of MPDL3280A (Anti-PD-L1 Antibody) in Pediatric and Young Adult Participants With Solid Tumors
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 30 and under
Trial IDs: GO29664, NCI-2015-01687, 2014-004697-41, NCT02541604
PROSTATE CANCER
Enzalutamide in Androgen Deprivation Therapy With Radiation Therapy for High Risk, Clinically Localized, Prostate Cancer
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: ANZUP1303, NCI-2015-01658, ACTRN12614000126617, NCT02446444
Enzalutamide and Leuprolide Acetate after Radiation Therapy in Treating Patients with High-Risk Prostate Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 15558, NCI-2015-01757, 147883, CC #15558, NCI-2015-01748, NCT02508636
Multiparametric MRI-Based Active Surveillance in Monitoring Patients with Low Risk Prostate Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Diagnostic
Age: 40 and over
Trial IDs: MCC-14-10633, NCI-2015-01739, 02147, NCT02564549
Enzalutamide and Cabazitaxel in Treating Patients with Metastatic, Hormone-Resistant Prostate Cancer
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: IRB00011227, NCI-2015-01103, 11227, CRS00001390, NCT02522715
LY2452473 in Improving Symptom Management in Patients with Undetectable PSA after Surgery for Prostate Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Supportive care
Age: 19 and over
Trial IDs: 15-120, NCI-2015-01601, NCT02499497
Rectal Spacer in Reducing Radiation Toxicity to Rectum in Patients with Low-Risk Prostate Cancer Undergoing Stereotactic Body Radiation Therapy
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: STU 092013-013, NCI-2014-02121, NCT02353832
Metformin Hydrochloride and Aspirin in Treating Patients with Hormone-Dependent Prostate Cancer That Has Progressed after Surgery or Radiation Therapy
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 081501, NCI-2015-00397, NCT02420652
Safety, Preliminary Efficacy and Pharmacokinetics of ASN001 in Metastatic Castrate Resistant Prostate Cancer
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: ASN001-101, NCI-2015-01712, NCT02349139
Sirolimus, Docetaxel, and Carboplatin in Treating Patients with Metastatic Hormone-Resistant Prostate Cancer
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 9388, NCI-2015-01478, NCT02565901
THYROID CANCER
TORC1/2 Inhibitor INK128 in Treating Patients with Newly Diagnosed or Refractory/Metastatic Anaplastic Thyroid Cancer
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 14-223, NCI-2015-01607, NCT02244463
MISCELLANEOUS/MULTIPLE/OTHER
Continued, Long-Term Follow-Up and Lenalidomide Maintenance Therapy for Patients on BMT CTN 0702 Protocol (BMT CTN 07LT)
Phase: Phase III
Type: Natural history/Epidemiology
Age: 18 to 70
Trial IDs: BMTCTN07LT, NCI-2015-01752, U01HL069294-05, NCT02322320
A Study Evaluating the Safety and Efficacy of the LentiGlobin(R) BB305 Drug Product in Beta-Thalassemia Major Subjects
Phase: Phase II, Phase I
Type: Treatment
Age: 12 to 35
Trial IDs: HGB-204, NCI-2015-01667, NCT01745120
PLX3397 and Sirolimus in Treating Patients with Sarcoma or Malignant Peripheral Nerve Sheath Tumors That Cannot Be Removed by Surgery
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: AAAO6059, NCI-2015-01768, NCT02584647
Stereotactic Body Radiation Therapy and Vertebroplasty in Treating Pain in Patients with Localized Spinal Metastasis
Phase: Phase II
Type: Supportive care, Treatment
Age: 18 and over
Trial IDs: STU 072010-134, NCI-2015-01674, SCCC-112008-022, 112008-022, SBRT Spine, NCT00855803
Imetelstat Sodium in Treating Patients With Primary or Secondary Myelofibrosis
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: CR107110, NCI-2014-02218, CP14B019, NCT01731951
Topical Menthol Cream in Reducing Pain in Patients with Chemotherapy Induced Peripheral Neuropathy
Phase: Phase II
Type: Supportive care
Age: 18 and over
Trial IDs: AAAL2664, NCI-2015-01613, CF-AAAM4210, NCT01855607
Idelalisib in Treating Patients with Relapsed or Refractory Waldenstrom Macroglobulinemia
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 15-040, NCI-2015-01605, NCT02439138
Gallium Ga 68-Edotreotide PET/CT in Imaging Patients with Somatostatin Receptor Positive Tumors
Phase: Phase II
Type: Diagnostic
Age: 6 months and over
Trial IDs: 201503708, NCI-2015-01588, NCT02441062